Relevant Studies and Literature
The Take2 Prophecy™ Test for NPC utilises the pioneering technology invented by an award-winning research team from the Chinese University of Hong Kong (CUHK). The technologies has been validated by large-scale clinical study involving 20,000 individuals and the research was published in the globally respected New England Journal of Medicine and Proceedings of the National Academy of Sciences of the United States of America. The reports and results can be viewed here:
Sequencing-based counting and size profiling of plasma Epstein–Barr virus DNA enhance population screening of nasopharyngeal carcinoma
Contributed by Y. M. Dennis Lo, April 26, 2018 (sent for review March 13, 2018; reviewed by Luis Diaz and Klaus Pantel)
Analysis of Plasma Epstein–Barr Virus DNA to Screen for Nasopharyngeal Cancer
Circulating cell-free Epstein–Barr virus (EBV) DNA is a biomarker for nasopharyngeal carcinoma. We conducted a prospective study to investigate whether EBV DNA in plasma samples would be useful to screen for early nasopharyngeal carcinoma in asymptomatic persons.